LYEL News and Press, Lyell Immunopharma Inc. From 01/31/22

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced the appointment of Gary Lee, Ph.D., as Chief Scientific Officer. A ...

SOUTH SAN FRANCISCO, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, announced today that the U.S. Food and Drug Administration (FDA) has cleared an Inv...

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (NASDAQ: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that members of its senior management team will participate in the ...

Gainers: MedAvail (NASDAQ:MDVL) +17%, Altamira Therapeutics (NASDAQ:CYTO) +17%, Orchard Therapeutics (NASDAQ:ORTX) +10%,Biofrontera (NASDAQ:BFRI) +9%, XORTX Therapeutics (NASDAQ:XRTX) +7%. Losers: Chembio Diagnostics (NASDAQ:CEMI) -16%, Gamida Cell (NAS...

Gainers: Spruce Biosciences (NASDAQ:SPRB) +30%. Coherus BioSciences (NASDAQ:CHRS) +11%. TPI Composites (NASDAQ:TPIC) +6%. Lyell Immunopharma (NASDAQ:LYEL) +4%. Aquestive Therapeutics (NASDAQ:AQST) +4%. Losers: Adagio Therapeutics (NASDAQ:ADGI) -5%. Leslie's (NASDAQ:LESL) -3%. Rivian Automotiv...

Lyell Immunopharma (NASDAQ:LYEL) announced that the FDA cleared the company’s Investigational New Drug (IND) application to begin a Phase 1 clinical trial for its chimeric antigen receptor (CAR) T-cell candidate, LYL797. Therefore, LYL797, targeted at patients with receptor tyrosine ki...

Expects to begin screening patients for the Phase 1 clinical trial by the end of the first quarter; initial data presentation expected in 2023 ROR1-targeted CAR T-cell therapy designed to overcome T-cell exhaustion and promote durable stemness incorporates Lyell’s novel genet...

Lyell’s cGMP-compliant manufacturing facility, is designed to produce cell products at scale for upcoming clinical trials across its CAR, TIL and TCR programs LyFE Manufacturing Center integrates digital data analytics into processes for real-time production monitoring and opti...

Lyell Immunopharma (NASDAQ:LYEL) announced the return of the company’s Chair of the Board of Directors, Rick Klausner, to resume his role after a temporary medical leave. “First and foremost, we are thankful that Rick is in great health, and we are excited to have him resume his...

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that Dr. Rick Klausner is resuming his role as Chair of Lye...